1. Parker-Lue S, Santoro M, Koski G. The ethics and economics of pharmaceutical pricing. Annual review of pharmacology and toxicology. 2015;55:191-206.
2. Vogler S, Paris V, Ferrario A, Wirtz VJ, de Joncheere K, Schneider P, et al. How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries. Applied health economics and health policy. 2017;15(3):307-21.
3. Light DW, Kantarjian H. Market spiral pricing of cancer drugs. Cancer. 2013;119(22):3900-2.
4. Teferra S, Hanlon C, Beyero T, Jacobsson L, Shibre T. Perspectives on reasons for non-adherence to medication in persons with schizophrenia in Ethiopia: a qualitative study of patients, caregivers and health workers. BMC psychiatry. 2013;13(1):1-9.
5. Bigdeli M, Laing R, Tomson G, Babar ZU. Medicines and universal health coverage: challenges and opportunities. Journal of pharmaceutical policy and practice. 2015;8(1).
6. Ghebreyesus TA. All roads lead to universal health coverage. LancetGlobal health. 2017;5(9):e839-e40.
7. Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, De Joncheere CP, Ewen MA, et al. Essential medicines for universal health coverage. 2017.
8. World Health Organization. WHO guideline on country pharmaceutical pricing policies, second edition. Second ed. Geneva: World Health Organization, Pg 1; 2020.
9. Acosta A, Acosta A, Ciapponi A, Aaserud M, Vietto V, Austvoll-Dahlgren A, et al. Pharmaceutical policies: Effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst Rev Cochrane Database of Systematic Reviews. 2014;2014(10).
10. Robinson JC, Whaley CM, Brown TT. Association of Reference Pricing with Drug Selection and Spending. New England journal of medicine. 2017;377(7):658-65.
11. World Health Organization. Assessment of medicine pricing and reimbursement systems in health insurance schemes. 2016.
12. Wouters OJ, Kanavos PG, McKee M. Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending. 2017.
13. Galizzi MM, Ghislandi S, Miraldo M. Effects of Reference Pricing in Pharmaceutical Markets : A Review. Pharmacoeconomics PharmacoEconomics. 2011;29(1):17-33.
14. Adriaen M, De Witte K, Simoens S. Pricing strategies of originator and generic medicines following patent expiry in Belgium. Journal of Generic Medicines. 2008;5(3):175-87.
15. Bashaar M, Hassali MA, Saleem F, A.A AL, Thawani V, Babar ZUD. Efficacy of international approaches to medicine price regulation and control: A scoping review. J Appl Pharm Sci Journal of Applied Pharmaceutical Science. 2017;7(4):227-41.
16. Beall RF, Nickerson JW, Attaran A. Pan-Canadian overpricing of medicines: A 6-country study of cost control for generic medicines. Open Med Open Medicine. 2014;8(4):130-5.
17. Cho MH, Yoo KB, Lee HY, Lee KS, Kwon JA, Han KT, et al. The effect of new drug pricing systems and new reimbursement guidelines on pharmaceutical expenditures and prescribing behavior among hypertensive patients in Korea. Health policy (Amsterdam, Netherlands). 2015;119(5):604-11.
18. Woutersa OJ, Kanavosa PG. Transitioning to a national health system in Cyprus: a stakeholder analysis of pharmaceutical policy reform. Bulletin of the World Health Organization. 2015;93:606-13.
19. Frye JE. International drug price indicator guide. Arlington, VA: Management Sciences for Health[Google Scholar]. 2012.
20. Hinsch M, Kaddar M, Schmitt S. Enhancing medicine price transparency through price information mechanisms. Globalization and health. 2014;10(1):1-11.
21. World Health Organization, Health Action International. Measuring medicine prices, availability, affordability and price components. [Geneva]; [Amersterdam]: World Health Organization ; Health Action International; 2008.
22. Nguyen TA, Knight R, Roughead EE, Brooks G, Mant A. Policy options for pharmaceutical pricing and purchasing: issues for low-and middle-income countries. Health policy and planning. 2015;30(2):267-80.
23. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. Bmj. 2021;372:n160.
24. Mirzoev T, Koduah A, de Chavez AC, Baatiema L, Danso-Appiah A, Ensor T, et al. Implementation of medicines pricing policies in sub-Saharan Africa: protocol for a systematic review. BMJ open. 2021;11(2):e044293.
25. World Health Organization. Institutional Repository for Information Sharing (IRIS) https://apps.who.int/iris/ 2021 [
26. World Bank. Open Knowledge Repository (OKR) https://openknowledge.worldbank.org/ 2021 [
27. University of Montreal. Erudit (Observatoire des sciences et des technologies) https://www.erudit.org/en/ 2021 [
28. Cairn International. Cairn Info International https://www.cairn.info/ 2021 [
29. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. Journal of clinical epidemiology. 2016;75:40-6.
30. Ahmad NS, Makmor-Bakry M, Hatah E. Drug price transparency initiative: A scoping review. Res Social Adm Pharm. 2020;20:20.
31. Eaton J. Ensuring access to psychotropic medication in sub-Saharan Africa. African Journal of Psychiatry (South Africa). 2008;11(3):179-81.
32. Mousnad MA, Shafie AA, Ibrahim MI. Systematic review of factors affecting pharmaceutical expenditures. Health Policy. 2014;116(2-3):137-46.
33. Pereira S, Jawahar N. The development and future of BRICS countries in the pharmaceutical sector. Journal of Pharmaceutical Sciences and Research. 2018;10(6):1336-41.
34. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Systematic reviews. 2016;5(1):1-10.
35. Snilstveit B, Oliver S, Vojtkova M. Narrative approaches to systematic review and synthesis of evidence for international development policy and practice. Journal of Development Effectiveness. 2012;4(3):409-29.
36. Assefa Y, Hill PS, Ulikpan A, Williams OD. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness? Globalization and health. 2017;13(1):1-11.
37. Bangalee V, Suleman F. Has the increase in the availability of generic drugs lowered the price of cardiovascular drugs in South Africa? Health SA Gesondheid. 2016;21:60-6.
38. Bangalee V, Suleman F. Pseudo-Generics in South Africa: A Price Comparison. Value in health regional issues. 2019;19:87-91.
39. d'Almeida C, Essi M-J, Camara M, Coriat B. Access to second-line antiretroviral therapeutic regimens in low-resource settings: experiences from Cameroon. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2011;57:S55-S8.
40. Liu Y, Galárraga O. Do national drug policies influence antiretroviral drug prices? Evidence from the Southern African Development community. Health policy and planning. 2017;32(2):170-7.
41. Moodley R, Suleman F. Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis. BMC health services research. 2019;19(1):1-13.
42. Moodley R, Suleman F. The impact of the single exit price policy on a basket of generic medicines in South Africa, using a time series analysis from 1999 to 2014. Plos one. 2019;14(7):e0219690.
43. Nicolosi E, Gray A. Potential cost savings from generic medicines—protecting the prescribed minimum benefits. South African Family Practice. 2009;51(1):59-63.
44. Rothberg A, Blignault J, Serfontein C, Valodia B, Eekhout S, Pels L. Experience of a medicines reference-pricing model. South African Medical Journal. 2004;94(3):183-8.
45. Steyn R, Burger JR, Serfontein JHP, Lubbe MS. Influence of a new reference‐based pricing system in South Africa on the prevalence and cost of antidiabetic medicine: a pilot study. International Journal of Pharmacy Practice. 2007;15(4):307-11.
46. Suleman F, Cassar K. The impact of international benchmarking on the price of immunosuppressive medicines for transplant recipients in South Africa. South African Medical Journal. 2019;109(11):865-71.
47. Walwyn DR, Nkolele AT. An evaluation of South Africa’s public–private partnership for the localisation of vaccine research, manufacture and distribution. Health research policy and systems. 2018;16(1):1-17.
48. Ye Y, Arnold F, Noor A, Wamukoya M, Amuasi J, Blay S, et al. The Affordable Medicines Facility-malaria (AMFm): are remote areas benefiting from the intervention? Malaria Journal. 2015;14(1):398.
49. Tougher S, Mann AG, Ye Y, Kourgueni IA, Thomson R, Amuasi JH, et al. Improving access to malaria medicine through private-sector subsidies in seven African countries. Health Aff (Millwood). 2014;33(9):1576-85.
50. Wiedenmayer K, Mbwasi R, Mfuko W, Mpuya E, Charles J, Chilunda F, et al. Jazia prime vendor system-a public-private partnership to improve medicine availability in Tanzania: from pilot to scale. Journal of pharmaceutical policy and practice. 2019;12(1):1-10.
51. Cohen JL, Yadav P, Moucheraud C, Alphs S, Larson PS, Arkedis J, et al. Do price subsidies on artemisinin combination therapy for malaria increase household use? Evidence from a repeated cross-sectional study in remote regions of Tanzania. PLoS One. 2013;8(7):e70713.
52. Ali G, Yahia A. Controlling medicine prices in Sudan: the challenge of the recently established medicines regulatory authority. EMHJ-Eastern Mediterranean Health Journal, 18 (8), 811-820, 2012. 2012.
53. Maiga D, Maiga S, Maiga M. Mechanism and implication of regulation of the pricing of essential medicines in the private pharmaceutical sector in Mali. Medecine tropicale: revue du Corps de sante colonial. 2010;70(2):184-8.
54. Ongarora D, Karumbi J, Minnaard W, Abuga K, Okungu V, Kibwage I. Medicine Prices, Availability, and Affordability in Private Health Facilities in Low-Income Settlements in Nairobi County, Kenya. Pharmacy (Basel). 2019;7(2).
55. Ali GKM. Accessibility of medicines and primary health care: The impact of the revolving drug fund in Khartoum State. African Journal of Pharmacy and Pharmacology. 2009;3(3):070-7.
56. de Jager H, Suleman F. The impact of generics and generic reference pricing on candesartan and rosuvastatin utilisation, price and expenditure in South Africa. International journal of clinical pharmacy. 2019;41(1):81-7.
57. Fink G, Dickens WT, Jordan M, Cohen JL. Access to subsidized ACT and malaria treatment—evidence from the first year of the AMFm program in six districts in Uganda. Health policy and planning. 2014;29(4):517-27.
58. Guimier JM, Candau D, Garenne M, Teulières L. Why drug prices are high in sub-Saharan Africa. Analysis of price structure: the case of Senegal. Cahiers d'études et de recherches francophones/Santé. 2005;15(1):41-52.
59. Honda A, Hanson K. Do equity funds protect the poor? Case studies from north-western Madagascar. Health policy and planning. 2013;28(1):75-89.
60. Maïga D, Williams-Jones B. Assessment of the impact of market regulation in Mali on the price of essential medicines provided through the private sector. Health Policy. 2010;97(2-3):130-5.
61. Ponsar F, Van Herp M, Zachariah R, Gerard S, Philips M, Jouquet G. Abolishing user fees for children and pregnant women trebled uptake of malaria-related interventions in Kangaba, Mali. Health policy and planning. 2011;26(suppl_2):ii72-ii83.
62. Sabot OJ, Mwita A, Cohen JM, Ipuge Y, Gordon M, Bishop D, et al. Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania. PLoS One. 2009;4(9):e6857.
63. Smith N, Obala A, Simiyu C, Menya D, Khwa-Otsyula B, O'Meara WP. Accessibility, availability and affordability of anti-malarials in a rural district in Kenya after implementation of a national subsidy scheme. Malaria Journal. 2011;10(1):1-9.
64. Ashigbie PG, Azameti D, Wirtz VJ. Challenges of medicines management in the public and private sector under Ghana’s National Health Insurance Scheme–A qualitative study. Journal of pharmaceutical policy and practice. 2016;9(1):1-10.
65. Wilson KR, Kohler JC, Ovtcharenko N. The make or buy debate: considering the limitations of domestic production in Tanzania. Globalization and health. 2012;8(1):1-9.
66. Tran DN, Manji I, Njuguna B, Kamano J, Laktabai J, Tonui E, et al. Solving the problem of access to cardiovascular medicines: revolving fund pharmacy models in rural western Kenya. BMJ Global Health. 2020;5(11):e003116.
67. Maïga FI, Haddad S, Fournier P, Gauvin L. Public and private sector responses to essential drugs policies: a multilevel analysis of drug prescription and selling practices in Mali. Social Science & Medicine 2003;57(5):937-48.
68. Abdel Rida N, Mohamed Ibrahim MI, Babar Z-U-D, Owusu Y. A systematic review of pharmaceutical pricing policies in developing countries. JPHS Journal of Pharmaceutical Health Services Research. 2017;8(4):213-26.
69. Danzon PM, Chao L-W. Does regulation drive out competition in pharmaceutical markets? The Journal of Law and Economics. 2000;43(2):311-58.
70. Henry D, Searles A. Chapter 9: Pharmaceutical Pricing Policy. Management Sciences for Health, MDS-3: Managing Access to Medicines and Health Technologies. 2012.
71. Sood N, De Vries H, Gutierrez I, Lakdawalla DN, Goldman DP. The Effect Of Regulation On Pharmaceutical Revenues: Experience In Nineteen Countries: If the United States implemented price controls and negotiations similar to those in other developed countries, US revenues would fall by as much as 20.3 percent. Health Affairs. 2008;27(Suppl1):w125-w37.
72. Selvaraj S, Hasan H, Chokshi M, Sengupta A, Guha A, Shiva M, et al. Pharmaceutical pricing policy: a critique. Economic and Political Weekly. 2012:20-3.
73. Dylst P, Simoens S. Generic Medicine Pricing Policies in Europe: Current Status and Impact. Pharmaceuticals (Basel). 2010;3(3):471-81.
74. Suzuki M, Webb D, Small R. Competing Frames in Global Health Governance: An Analysis of Stakeholder Influence on the Political Declaration on Non-communicable Diseases. Int J Health Policy Manag. 2021:-.
75. Balane MA, Palafox B, Palileo-Villanueva LM, McKee M, Balabanova D. Enhancing the use of stakeholder analysis for policy implementation research: towards a novel framing and operationalised measures. BMJ Global Health. 2020;5(11):e002661.
76. Ancker S, Rechel B. HIV/AIDS policy-making in Kyrgyzstan: a stakeholder analysis. Health Policy and Planning. 2015;30(1):8-18.
77. Brugha R, Varvasovszky Z. Stakeholder analysis: a review. Health Policy and Planning. 2000;15(3):239-46.
78. Parashar R, Gawde N, Gilson L. Application of “Actor Interface Analysis” to Examine Practices of Power in Health Policy Implementation: An Interpretive Synthesis and Guiding Steps. International Journal of Health Policy and Management. 2020:-.
79. Lehmann U, Gilson L. Actor interfaces and practices of power in a community health worker programme: a South African study of unintended policy outcomes. Health Policy Plan. 2013;28(4):358-66.
80. Cleary S, Molyneux S, Gilson L. Resources, attitudes and culture: an understanding of the factors that influence the functioning of accountability mechanisms in primary health care settings. BMC Health Services Research. 2013;13(1):320.
81. Sriram V, Topp SM, Schaaf M, Mishra A, Flores W, Rajasulochana SR, et al. 10 best resources on power in health policy and systems in low- and middle-income countries. Health Policy and Planning. 2018;33(4):611-21.
82. Regmi K, Mudyarabikwa O. A systematic review of the factors - barriers and enablers - affecting the implementation of clinical commissioning policy to reduce health inequalities in the National Health Service (NHS), UK. Public Health. 2020;186:271-82.
83. Vejaratnam N, Mohamad ZF, Chenayah S. A systematic review of barriers impeding the implementation of government green procurement. Journal of Public Procurement. 2020;20(4):451-71.
84. Anggriani Y, Ibrahim MIM, Suryawati S, Shafie AA. The impact of Indonesian generic medicine pricing policy on medicine prices. Journal of Generic Medicines. 2013;10(3-4):219-29.
85. Kaló Z, Alabbadi I, Al Ahdab OG, Alowayesh M, Elmahdawy M, Al-Saggabi AH, et al. Implications of external price referencing of pharmaceuticals in Middle East countries. Expert review of pharmacoeconomics & outcomes research. 2015;15(6):993-8.
86. Mirzoev T, Das M, Ebenso B, Uzochukwu B, Rawat B, Blok L, et al. Contextual influences on the role of evidence in health policy development: what can we learn from six policies in India and Nigeria? Evidence & Policy: A Journal of Research, Debate and Practice. 2017;13(1):59-79.
87. Koduah A, van Dijk H, Agyepong IA. The role of policy actors and contextual factors in policy agenda setting and formulation: maternal fee exemption policies in Ghana over four and a half decades. Health Research Policy and Systems. 2015;13(1):27.
88. Verboom B, Baumann A. Mapping the Qualitative Evidence Base on the Use of Research Evidence in Health Policy-Making: A Systematic Review. Int J Health Policy Manag. 2020:-.
89. Mirzoev T, Poudel AN, Gissing S, Doan TTD, Ferdous T, Regmi S, et al. Is evidence-informed urban health planning a myth or reality? Lessons from a qualitative assessment in three Asian cities. Health Policy Plan. 2019;34(10):773-83.
90. Shroff Z, Aulakh B, Gilson L, Agyepong I, El-Jardali F, Ghaffar A. Incorporating research evidence into decision-making processes: researcher and decision-maker perceptions from five low- and middle-income countries. Health Research Policy and Systems. 2015;13(1):70.
91. Moat KA, Lavis JN. 10 best resources for … evidence-informed health policy making. Health Policy and Planning. 2013;28(2):215-8.
92. Mirzoev T, Green A, Gerein N, Pearson S, Bird P, Ha BTT, et al. Role of evidence in maternal health policy processes in Vietnam, India and China: findings from the HEPVIC project. Evidence & Policy: A Journal of Research, Debate and Practice. 2013;9(4):493-511.
93. Mbava N, Dahler-Larsen P. Evaluation in African contexts: The promises of participatory approaches in theory-based evaluations. African Evaluation Journal. 2019;7.
94. Ebenso B, Manzano A, Uzochukwu B, Etiaba E, Huss R, Ensor T, et al. Dealing with context in logic model development: Reflections from a realist evaluation of a community health worker programme in Nigeria. Evaluation and Program Planning. 2019;73:97-110.
95. Ogbuabor DC, Onwujekwe OE. Implementation of free maternal and child healthcare policies: assessment of influence of context and institutional capacity of health facilities in South-east Nigeria. Global Health Action. 2018;11(1):1535031.
96. Greenhalgh T, Pawson R, Wong G, Westhorp G, Greenhalgh J, Manzano A, et al. What realists mean by context; or, Why nothing works everywhere or for everyone: The Rameses II project; 2017.